WITHDRAWN: @entity1033 for treating XXXX .

@entity1 @entity1033 @entity198 @entity75 @entity10701 @entity344 @entity4764
BACKGROUND: @entity10701 is a highly contagious infection of the oral cavity which typically affects @entity1 but can also occur in adults. Symptoms may vary widely from mild discomfort to life-threatening @entity198 . OBJECTIVES: The objective of this review was to evaluate the effectiveness of systemic @entity1033 for @entity10701 . SEARCH METHODS: We searched the following databases: Cochrane Oral Health Group's Trials Register (to 22 May 2008); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 2); MEDLINE (1950 to 22 May 2008); and EMBASE (1980 to 22 May 2008). There were no language restrictions. SELECTION CRITERIA: Randomised controlled trials comparing @entity1033 to placebo in @entity1 and young adults < 25 years of age with a diagnosis of @entity10701 with or without herpes labialis were considered. DATA COLLECTION AND ANALYSIS: Two review authors independently and in duplicate screened and extracted information from, and assessed the risk of bias in the included clinical trials. The Cochrane Collaboration statistical guidelines were followed for data synthesis. MAIN RESULTS: Only two clinical trials, one with 72 @entity1 and the other with 20 @entity1 were included in this review. The second study failed to report several methodological items and was inconsistent in its reporting of the outcomes measurement.The first trial, with a moderate risk of bias, showed better results in the @entity1033 group compared to the placebo group in @entity1 < 6 years of age in reducing the number of individuals with @entity75 (risk ratio (RR) 0.10 (95% confidence interval (CI) 0.02 to 0.38)), new @entity75 (RR 0.04 (95% CI 0.00 to 0.65)), difficulty in eating (RR 0.14 (95% CI 0.03 to 0.58)), and drinking @entity4764 (RR 0.11 (95% CI 0.01 to 0.83)) after 8 days of treatment.Following the onset of treatment, three @entity1 from the placebo group were admitted to hospital for rehydration (P = 0.11). Four @entity1 (two from the @entity1033 , and two from the placebo group) showed mild @entity344 that resolved spontaneously after 24 to 48 hours without a change in the study treatment. AUTHORS' CONCLUSIONS: We found two relevant trials in this systematic review, only one of them could provide some weak evidence that @entity1033 is an effective treatment in reducing the number of @entity75 , preventing the development of new @entity75 , decreasing the number of individuals with @entity4764 experienced in eating and drinking and reducing hospital admission for @entity1 under 6 years of age with @entity10701 .
